You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

5391 Results
Guidelines and Advice
Status: Current
ID: 5-11
Version: 2
Jan 2022
Drug
Other Name(s): Alecensaro®
Quick Link(s): Drug Monograph, Patient Info Sheet
Nov 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
ODB - General Benefit
    procarbazine
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
riTUXimab (Unfunded),
methotrexate,
vinCRIStine,
procarbazine,
cytarabine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant
Funding:
Exceptional Access Program
    alectinib - Adjuvant treatment of ALK-positive non-small cell lung cancer, according to specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
alectinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2025
Document
New
Dec 2025
Document
New
Dec 2025
Document
New
Dec 2025
Document
New
Dec 2025
This page lists cancer resources to support First Nations, Inuit, Métis and urban Indigenous communities and organizations in Ontario. Find tools,...

Pages